athenahealth (NASDAQ:ATHN)‘s stock had its “buy” rating reiterated by stock analysts at KeyCorp in a note issued to investors on Friday. They currently have a $152.00 target price on the health services provider’s stock. KeyCorp’s price objective suggests a potential upside of 17.40% from the stock’s current price.

Several other analysts have also recently commented on the stock. Robert W. Baird reduced their price objective on shares of athenahealth from $170.00 to $155.00 and set an “outperform” rating for the company in a research note on Sunday, October 22nd. TheStreet cut shares of athenahealth from a “b-” rating to a “c+” rating in a research note on Wednesday, October 11th. First Analysis upgraded shares of athenahealth from an “underweight” rating to an “equal weight” rating and raised their price objective for the company from $125.00 to $127.00 in a research note on Monday, October 23rd. Leerink Swann set a $155.00 price objective on shares of athenahealth and gave the company a “hold” rating in a research note on Thursday, October 19th. Finally, Jefferies Group reduced their price objective on shares of athenahealth from $135.00 to $120.00 and set a “hold” rating for the company in a research note on Friday, September 15th. One analyst has rated the stock with a sell rating, seventeen have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $143.96.

Shares of athenahealth (ATHN) traded down $3.18 during midday trading on Friday, hitting $129.47. 509,300 shares of the company traded hands, compared to its average volume of 341,274. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.67 and a quick ratio of 1.67. athenahealth has a 12-month low of $95.01 and a 12-month high of $158.66. The firm has a market capitalization of $5,180.00, a PE ratio of 168.14, a price-to-earnings-growth ratio of 3.10 and a beta of 1.58.

athenahealth (NASDAQ:ATHN) last announced its quarterly earnings data on Thursday, October 19th. The health services provider reported $0.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.06. athenahealth had a net margin of 2.65% and a return on equity of 6.78%. The firm had revenue of $304.60 million during the quarter, compared to analysts’ expectations of $310.52 million. During the same quarter last year, the business earned $0.60 earnings per share. The business’s revenue for the quarter was up 10.1% compared to the same quarter last year. research analysts forecast that athenahealth will post 1.22 earnings per share for the current fiscal year.

In other news, SVP Bradford Kyle Armbrester sold 1,000 shares of athenahealth stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $128.56, for a total transaction of $128,560.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jonathan Bush sold 30,000 shares of athenahealth stock in a transaction dated Wednesday, December 26th. The stock was sold at an average price of $134.80, for a total transaction of $4,044,000.00. Following the sale, the chief executive officer now owns 320,807 shares of the company’s stock, valued at $43,244,783.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 69,700 shares of company stock valued at $9,375,172. 3.20% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ATHN. Schwab Charles Investment Management Inc. grew its holdings in shares of athenahealth by 6.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 170,978 shares of the health services provider’s stock worth $24,031,000 after buying an additional 9,960 shares in the last quarter. First Trust Advisors LP purchased a new stake in shares of athenahealth during the second quarter worth about $219,000. Legal & General Group Plc grew its holdings in shares of athenahealth by 11.2% during the second quarter. Legal & General Group Plc now owns 14,358 shares of the health services provider’s stock worth $2,018,000 after buying an additional 1,444 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of athenahealth by 123.8% during the second quarter. BNP Paribas Arbitrage SA now owns 1,345 shares of the health services provider’s stock worth $189,000 after buying an additional 744 shares in the last quarter. Finally, Prudential Financial Inc. grew its holdings in shares of athenahealth by 4.9% during the second quarter. Prudential Financial Inc. now owns 2,146 shares of the health services provider’s stock worth $302,000 after buying an additional 100 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/13/keycorp-reaffirms-buy-rating-for-athenahealth-athn.html.

About athenahealth

athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.

Analyst Recommendations for athenahealth (NASDAQ:ATHN)

Receive News & Ratings for athenahealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth and related companies with MarketBeat.com's FREE daily email newsletter.